Phase III study of Pomalidomide and low dose Dex with or without Pembrolizumab (MK3475) in MM

Clinical Trial Grant

Duke Scholars

Principal Investigator Cristina Gasparetto Medicine, Hematologic Malignancies and Cellular Therapy

Administered By

Duke Cancer Institute

Awarded By

Merck Sharp & Dohme

Start Date

May 1, 2016

End Date

April 30, 2021

Administered By

Duke Cancer Institute

Awarded By

Merck Sharp & Dohme

Start Date

May 1, 2016

End Date

April 30, 2021